NCT06308588 2026-04-14
Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
Clinical Trials
14 trialsNCT04971226 2026-04-06
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Novartis
Phase 3 Active not recruiting
NCT03874858 2026-04-02
DANTE
Novartis
Phase 2 Completed
NCT06368414 2026-04-02
AsterA
Korean Society of Hematology
Phase 2 Recruiting
NCT05143840 2026-03-23
ALERTCML
Augusta University
Phase 2 Recruiting
NCT07354074 2026-03-23
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Novartis
Phase 2 Not yet recruiting
NCT04948333 2026-03-18
Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
Novartis
Phase 3 Completed
NCT07039760 2026-03-11
Asciminib With or Without Sildenafil for Brain Tumors
Washington University School of Medicine
Phase EARLY_PHASE1 Not yet recruiting
NCT04877522 2026-03-06
Asciminib Roll-over Study
Novartis
Phase 4 Recruiting
NCT06236724 2026-03-04
Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06629584 2026-02-17
Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05456191 2026-02-06
ASC4START
Novartis
Phase 3 Active not recruiting
NCT06092879 2026-02-06
ASSURE-3
Novartis
Active not recruiting
NCT07387926 2026-02-04
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
Novartis
Phase 1/2 Not yet recruiting